Device Therapies Among Patients Receiving Primary Prevention Implantable Cardioverter-Defibrillators in the Cardiovascular Research Network.
- Citation data:
Journal of the American Heart Association, ISSN: 2047-9980, Vol: 7, Issue: 7, Page: 0
- Publication Year:
- Usage 12
- Abstract Views 8
- Bepress 7
- Bepress 1
- Downloads 4
- Bepress 3
- Bepress 1
- Repository URL:
- https://touroscholar.touro.edu/president_pubs/166; https://escholarship.umassmed.edu/oapubs/3419; https://touroscholar.touro.edu/cgi/viewcontent.cgi?article=1166&context=president_pubs; http://kpresearchpublications.kp.org/handle/kp/19595
- Medicine; arrhythmia; implantable cardioverter‐defibrillator; inappropriate shock; outcomes research; sudden cardiac death; Cardiology; Equipment and Supplies; Cardiovascular Diseases; Clinical Epidemiology; Epidemiology
- Most Recent Tweet View All Tweets
Primary prevention implantable cardioverter-defibrillators (ICDs) reduce mortality in selected patients with left ventricular systolic dysfunction by delivering therapies (antitachycardia pacing or shocks) to terminate potentially lethal arrhythmias; inappropriate therapies also occur. We assessed device therapies among adults receiving primary prevention ICDs in 7 healthcare systems.